Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $2.55.
Several research firms have recently weighed in on AVEO. Piper Jaffray Companies lifted their price objective on AVEO Pharmaceuticals from $3.00 to $4.00 and gave the company an “overweight” rating in a report on Tuesday, September 10th. HC Wainwright upgraded AVEO Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $1.00 to $1.75 in a report on Wednesday.
Several large investors have recently added to or reduced their stakes in AVEO. HCR Wealth Advisors bought a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $28,000. Anson Funds Management LP bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $33,000. Cetera Advisor Networks LLC bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $38,000. SG Americas Securities LLC bought a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $50,000. Finally, Jane Street Group LLC bought a new position in shares of AVEO Pharmaceuticals during the 2nd quarter valued at about $98,000. Institutional investors and hedge funds own 29.55% of the company’s stock.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.04. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.78 million. AVEO Pharmaceuticals had a negative return on equity of 50.69% and a negative net margin of 46.69%. Research analysts anticipate that AVEO Pharmaceuticals will post -0.08 EPS for the current fiscal year.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Story: Market Capitalization
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.